In an analysis of current supply deals for COVID-19 vaccines, the
ONE Campaign said wealthy countries, such as the United States and
Britain, should share the excess doses to "supercharge" a fully
global response to the pandemic.
The advocacy group, which campaigns against poverty and preventable
diseases, said a failure to do so would deny billions of people
essential protection from the COVID-19-causing virus and likely
prolong the pandemic.
The report looked specifically at contracts with the five leading
COVID-19 vaccine makers - Pfizer-BioNTech, Moderna, Oxford-AstraZeneca,
Johnson & Johnson, and Novavax.
It found that to date, the United States, the European Union,
Britain, Australia, Canada and Japan have already secured more than
3 billion doses - over a billion more than the 2.06 billion needed
to give their entire populations two doses.
"This huge excess is the embodiment of vaccine nationalism," said
Jenny Ottenhoff, ONE Campaign's senior director for policy.
[to top of second column] |
"Rich countries understandably
hedged their bets on vaccines early in the
pandemic but with these bets paying off in
spades, a massive course correction is needed if
we are going to protect billions of people
around the world," she added.
The analysis found that, along with other COVID
vaccine supplies procured by the global COVAX
vaccine-sharing plan and in bilateral deals, the
excess rich-country doses would go a long way to
protecting vulnerable people in poorer
countries.
This would significantly reduce the risk of
deaths from COVID-19, it said, as well as
limiting the chances of new virus variants
emerging and accelerating an end to the
pandemic.
The World Health Organization on Thursday urged
nations with vaccines not to share them
unilaterally, but to donate them to the global
COVAX scheme to ensure fairness.
(Reporting by Kate Kelland; Editing by Aurora
Ellis)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |